Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Immunotherapy. University of Pittsburgh School of Medicine, Pittsburg, PA, United States

Survival: 25.2 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: Pittsburg, PA
Hospital: University of Pittsburgh School of Medicine
Journal: Link
Date: 8/2009

Patients: This phase 2 study involved 31 women with platinum resistant or platinum refractory ovarian cancer. The median age was 51, ranging from 29 to 75 years of age.

Treatment: Patients were treated with interleukin-2 (IL-2), an immunotherapy. The IL-2 was delivered through a catheter into the peritoneal cavity.

Toxicity: A grade 4 catheter injury was reported in two women. Grade 3 toxicities included nausea, abdominal distention, and deep vein thrombosis.

Results: The median overall survival was 25.2 months (2.1 years).

Support: This study was supported in part by Chiron Therapeutics which markets IL-2 (aldesleukin) as PROLEUKIN®.

Correspondence: Dr. Robert P. Edwards

E-mail to a Friend Email Physician More Information